Please login to the form below

Not currently logged in
Email:
Password:

Eli Lilly

This page shows the latest Eli Lilly news and features for those working in and with pharma, biotech and healthcare.

Teva will have to endure revenue 'trough' in 2019

Teva will have to endure revenue 'trough' in 2019

Ajovy has a particularly tough time as it will compete head-to-head with similar CGRP inhibitor products from Amgen/Novartis and Eli Lilly already on the market, with others from

Latest news

  • Trulicity’s ascent lifts Lilly Trulicity’s ascent lifts Lilly

    Diabetes treatment leads new product growth. Impressive growth from diabetes treatment Trulicity has helped Eli Lilly to post 7% growth in its full year results. ... This year will also see Lilly expand its ambitions in cancer, most notably with the $8bn

  • Pfizer closes on EU approval of lung cancer drug Vizimpro Pfizer closes on EU approval of lung cancer drug Vizimpro

    from Eli Lilly, as well as biosimilars of AbbVie’s blockbuster anti-TNF drug Humira (adalimumab) for inflammatory and autoimmune diseases from Fresenius Kabi  called Idacio and Kromeya. ... from Janssen and Boehringer Ingelheim/Lilly’s Jardiance

  • EMA says Lilly’s Lartruvo should not be prescribed EMA says Lilly’s Lartruvo should not be prescribed

    First time EMA has acted on accelerated approval follow-up. The EU'S medicines regulator says doctors should stop prescribing Eli Lilly’s soft tissue cancer drug Lartruvo to new patients, ... Lilly said at the time it would stop promoting Lartruvo and

  • FDA adcomm split on Sanofi’s type 1 diabetes drug FDA adcomm split on Sanofi’s type 1 diabetes drug

    Current SGLT2-selective drugs – such as Johnson &Johnson’s Invokana, Eli Lilly/Boehringer Ingelheim's Jardiance and Farxiga from AstraZeneca – are approved only for type 2 diabetes.

  • Evenity back on track with FDA panel blessing in osteoporosis Evenity back on track with FDA panel blessing in osteoporosis

    The drug is currently under regulatory review in Europe. The closest direct rival to Evenity so far was an anti-sclerostin antibody developed by Eli Lilly called blosozumab, but that has

More from news
Approximately 75 fully matching, plus 532 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 2 fully matching, plus 27 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 29 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 19 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics